{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T12:19:00Z","timestamp":1781266740008,"version":"3.54.1"},"reference-count":17,"publisher":"SAGE Publications","issue":"9","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medicinal Food"],"published-print":{"date-parts":[[2014,9]]},"abstract":"<jats:p>\n                    The purpose of this study was to ascertain whether an oral, non-prescription, nutritional supplement compound composed of a proprietary alkali-buffered creatine monohydrate and cetylated fatty acids mixture (Kre-Celazine\n                    <jats:sup>\u00ae<\/jats:sup>\n                    ) was efficacious in reducing or eliminating refractory pain and inflammation, without untoward effects, in Juvenile Rheumatoid Arthritis (JRA), which is also called Juvenile Idiopathic Arthritis (JIA). JRA\/JIA is a patho-physiologically complex, chronic childhood autoimmune inflammatory disease of unknown etiology. Numerous studies have unsuccessfully attempted to pinpoint a possible common initiation event. Officially considered an affliction of children below the age of 16 years, an initial diagnosis has been confirmed in infants less than 1 year old, to individuals older then 17 years. In this study, sixteen juveniles, ages 7 through 16 years, experiencing long-standing, unremitting pain and inflammation despite previous use of prescription anti-inflammatory drugs and NSAIDs, were enrolled in a 30-day, open-label clinical study and treated with Kre-Celazine. Efficacy of this nutritional supplement was determined by the juvenile's personal physician and based on observations of the following: (1) significant reduction or elimination of palpable signs of inflammation; (2) renormalization of range of motion; (3) reduction or absence of perceived pain as reported to the physician by the patient; (4) renormalization of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) values. In addition, the individual's previous steroid or non-steroidal anti-inflamatory medication(s) were reduced or eliminated in a stepwise progressive fashion during the study.\n                  <\/jats:p>","DOI":"10.1089\/jmf.2013.0169","type":"journal-article","created":{"date-parts":[[2014,6,4]],"date-time":"2014-06-04T18:52:44Z","timestamp":1401907964000},"page":"1022-1026","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Kre-Celazine\n                    <sup>\u00ae<\/sup>\n                    as a Viable Treatment for Juvenile Rheumatoid Arthritis\/Juvenile Idiopathic Arthritis \u2014 A Pilot Study"],"prefix":"10.1177","volume":"17","author":[{"given":"Jeff","family":"Golini","sequence":"first","affiliation":[{"name":"All American Pharmaceutical and Natural Foods Corporation","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy Lou","family":"Jones","sequence":"additional","affiliation":[{"name":"Royal Knight Incorporated","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2014,9,1]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"1991","article-title":"Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997","volume":"25","author":"Petty RE","year":"1998","unstructured":"Petty RE, , Southwood TR, , Baum J, , Bhettay E, , Glass DN, , Manners P, et al.: Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol, 1998; 25:1991\u20131994.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_3_2","first-page":"1069","article-title":"Validation of the proposed ILAR classification criteria for juvenile idiopathic arthritis. International League of Associations for Rheumatology","volume":"27","author":"Foeldvari I","year":"2000","unstructured":"Foeldvari I, , Bidde M: Validation of the proposed ILAR classification criteria for juvenile idiopathic arthritis. International League of Associations for Rheumatology. J Rheumatol, 2000; 27:1069\u20131072.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_4_2","unstructured":"National Center for Chronic Disease Prevention and Health Promotion Division of Population Health: Childhood Arthritis. www.cdc.gov\/arthritis\/basics\/childhood.htm (accessed October2013)."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4160-0246-8.50007-3"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00247-006-0199-x"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.33.1.25"},{"key":"e_1_3_3_8_2","unstructured":"The Arthritis Foundation: Juvenile Arthritis Fact Sheet. www.arthritis.org\/ja-fact-sheet.php (accessed October2013)."},{"key":"e_1_3_3_9_2","first-page":"909","article-title":"Prognostic factors in juvenile chronic arthritis","volume":"9","author":"Dequeker J","year":"1982","unstructured":"Dequeker J, , Mardjuadi A: Prognostic factors in juvenile chronic arthritis. J Rheumatol, 1982; 9:909\u2013915.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_10_2","first-page":"763","article-title":"Response of systemic onset juvenile rheumatoid arthritis to etanercept: is the glass half full or half empty?","volume":"32","author":"Eberhard BA","year":"2005","unstructured":"Eberhard BA, , Ilowite NT: Response of systemic onset juvenile rheumatoid arthritis to etanercept: is the glass half full or half empty?. J Rheumatol, 2005; 32:763\u2013765.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780290216"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600830307"},{"key":"e_1_3_3_13_2","first-page":"1708","article-title":"Cetylated fatty acids improve knee function in patients with osteoarthritis","volume":"29","author":"Hesslink R","year":"2002","unstructured":"Hesslink RJr, , Armstrong D3rd, , Nagendran MV, , Sreevatsan S, , Barathur R: Cetylated fatty acids improve knee function in patients with osteoarthritis. J Rheumatol, 2002; 29:1708\u20131712.","journal-title":"J Rheumatol"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0162-3109(00)00221-6"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/71.1.349S"},{"key":"e_1_3_3_16_2","first-page":"475","article-title":"A cetylated fatty acid topical cream with menthol reduces pain and improves functional performance in individuals with arthritis","volume":"19","author":"Kraemer WJ","year":"2005","unstructured":"Kraemer WJ, , Ratamess NA, , Maresh CM, , Anderson JA, , Volek JS, , Tiberio DP, et al.: A cetylated fatty acid topical cream with menthol reduces pain and improves functional performance in individuals with arthritis. J Strength Cond Res, 2005; 19:475\u2013480.","journal-title":"J Strength Cond Res"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000003"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705316"}],"container-title":["Journal of Medicinal Food"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jmf.2013.0169","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jmf.2013.0169","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jmf.2013.0169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:21:27Z","timestamp":1777645287000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jmf.2013.0169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["10.1089\/jmf.2013.0169"],"URL":"https:\/\/doi.org\/10.1089\/jmf.2013.0169","relation":{},"ISSN":["1096-620X","1557-7600"],"issn-type":[{"value":"1096-620X","type":"print"},{"value":"1557-7600","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}